The U.S. Food and Drug Administration has approved a new buprenorphine treatment option for opioid use disorder
For immediate release: May 23, 2023 Today, the U.S. Food and Drug Administration approved Brixadi (buprenorphine) extended-release injection for subcutaneous (under the skin) use to treat moderate to severe opioid use disorder (OUD). Brixadi is available in two formulations, a weekly injection that can be used in patients who have started treatment with a single …